- Home
- RARE vs CCOI Comparison
RARE vs CCOI Comparison
Compare RARE & CCOI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- CCOI
- Stock Information
- Founded
- RARE 2010
- CCOI 1999
- Country
- RARE United States
- CCOI United States
- Employees
- RARE N/A
- CCOI N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- CCOI Telecommunications Equipment
- Sector
- RARE Health Care
- CCOI Consumer Discretionary
- Exchange
- RARE Nasdaq
- CCOI Nasdaq
- Market Cap
- RARE 2.6B
- CCOI 2.4B
- IPO Year
- RARE 2014
- CCOI N/A
- Fundamental
- Price
- RARE $29.96
- CCOI $38.23
- Analyst Decision
- RARE Strong Buy
- CCOI Buy
- Analyst Count
- RARE 14
- CCOI 8
- Target Price
- RARE $86.64
- CCOI $60.50
- AVG Volume (30 Days)
- RARE 1.4M
- CCOI 2.0M
- Earning Date
- RARE 08-05-2025
- CCOI 08-07-2025
- Dividend Yield
- RARE N/A
- CCOI 10.62%
- EPS Growth
- RARE N/A
- CCOI N/A
- EPS
- RARE N/A
- CCOI N/A
- Revenue
- RARE $610,159,000.00
- CCOI $921,889,000.00
- Revenue This Year
- RARE $19.72
- CCOI $5.37
- Revenue Next Year
- RARE $23.29
- CCOI $6.45
- P/E Ratio
- RARE N/A
- CCOI N/A
- Revenue Growth
- RARE 26.77
- CCOI N/A
- 52 Week Low
- RARE $25.81
- CCOI $29.62
- 52 Week High
- RARE $60.37
- CCOI $86.76
- Technical
- Relative Strength Index (RSI)
- RARE 53.11
- CCOI 43.97
- Support Level
- RARE $29.04
- CCOI $36.74
- Resistance Level
- RARE $30.61
- CCOI $38.48
- Average True Range (ATR)
- RARE 0.80
- CCOI 1.77
- MACD
- RARE 0.31
- CCOI 0.62
- Stochastic Oscillator
- RARE 79.81
- CCOI 89.54
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About CCOI Cogent Communications Holdings Inc.
Cogent carries over one fifth of the world's internet traffic over its network and is a broadband provider for businesses. Cogent's corporate customers are in high-rise office buildings, where the firm provides two types of connections: dedicated internet access, which connects them to the internet, and virtual private networking, which offers an internal network for employees in different locations. Cogent's corporate customers are exclusively in North America and account for nearly half of the firm's revenue. Cogent's netcentric customers include internet service providers and content providers, to which Cogent provides internet transit. They hand traffic to Cogent in data centers and rely on Cogent to deliver it. About half of netcentric revenue is from outside the US.